Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s pipeline products include VAL201 for the indication of prostate cancer, breast and ovarian cancer; VAL301 targets endometriosis; BC201 for hyperimmune response in patients after SARS-CoV2 infection and sepsis; and CLX001 for triple negative breast cancer and ovarian cancer. Its therapeutic areas include oncology and women's health. The company operates through its subsidiaries in the UK. ValiRx is headquartered in Nottingham, England, the UK.
Headquarters
United Kingdom
Address
Medicity Nottingham, D6 Thane Road, England, NG906BH
Website
www.valirx.com
Telephone
44 115 7840026
No of Employees
11
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VAL (LON)
Revenue (2024)
$39,500
-37%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-16.5%
(2024 vs 2023)
Market Cap*
$2.5M
Net Profit Margin (2024)
XYZ
-84.9%
(2024 vs 2023)
* As of and is in US$
ValiRx Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| VAL201: |
| Prostate Cancer |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In February, the company entered into a contract with Screenin3d Limited to provide Inaphaea's patient-derived cells for evaluation and commercial use. |
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with the University of Dundee and its Drug Discovery Unit for mechanism of action studies. |
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with STINGRAY BIO to investigate a lead series of drug candidates for use in oncology. |
Competitor Comparison
| Key Parameters | ValiRx Plc | Avacta Group Plc | Ellipses Pharma Ltd | HOX Therapeutics Ltd | TheraCryf plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | Nottingham | London | London | Guildford | Netherton |
| State/Province | England | England | England | Oxfordshire | England |
| No. of Employees | 11 | 81 | - | - | 9 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark Edward Eccleston | Director; Chief Executive Officer | Executive Board | 2024 | 55 |
| Gerry Desler | Director; Secretary; Chief Financial Officer | Executive Board | 2022 | 81 |
| Michelle Barnard | Director - Research | Senior Management | 2025 | - |
| Martin John Gouldstone | Chairman | Non Executive Board | 2024 | 60 |
| Catherine Jane Tralau-Stewart | Director | Non Executive Board | 2024 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer